|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Arcadia Biosciences insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Arcadia Biosciences insider buys are important for investors to follow.
Date | Insider | Price | Amount |
8-4-2023 Insider Buy |
Thomas J. Schaefer Chief Financial Officer |
$3.67
CAGR »
|
$2,381.83 649 shares |
5-30-2023 Insider Buy |
Stanley Jacot Jr. Chief Executive Officer |
$4.31
CAGR »
|
$21,550.00 5,000 shares |
8-1-2022 Insider Buy |
Pamela Haley Chief Financial Officer |
$0.70
CAGR »
|
$490.00 700 shares |
8-3-2020 Insider Buy |
Randall Shultz Chief Technology Officer |
$3.16
CAGR »
|
$2,212.00 700 shares |
8-3-2020 Insider Buy |
Matthew T. Plavan Chief Executive Officer |
$3.16
CAGR »
|
$1,848.60 585 shares |
8-3-2020 Insider Buy |
Pamela Haley Chief Financial Officer |
$3.16
CAGR »
|
$2,212.00 700 shares |
2-3-2020 Insider Buy |
Matthew T. Plavan Chief Executive Officer |
$1.72
CAGR »
|
$1,204.00 700 shares |
2-3-2020 Insider Buy |
Sarah Reiter Chief Commercial Officer |
$1.72
CAGR »
|
$1,204.00 700 shares |
2-3-2020 Insider Buy |
Pamela Haley Chief Financial Officer |
$1.72
CAGR »
|
$1,204.00 700 shares |
11-19-2019 Insider Buy |
Sarah Reiter Chief Commercial Officer |
$4.52
CAGR »
|
$4,520.00 1,000 shares |
11-18-2019 Insider Buy |
Lilian Shackelford Murray Director |
$4.25
CAGR »
|
$21,250.00 5,000 shares |
11-14-2019 Insider Buy |
Matthew T. Plavan Chief Executive Officer |
$4.08
CAGR »
|
$4,079.50 1,000 shares |
9-23-2019 Insider Buy |
Matthew T. Plavan Chief Executive Officer |
$5.25
CAGR »
|
$10,500.00 2,000 shares |
9-17-2019 Insider Buy |
Kevin Comcowich Director |
$5.88
CAGR »
|
$29,388.00 5,000 shares |
9-10-2019 Insider Buy |
Matthew T. Plavan Chief Executive Officer |
$6.51
CAGR »
|
$13,013.50 2,000 shares |
9-10-2019 Insider Buy |
Kevin Comcowich Director |
$6.49
CAGR »
|
$97,333.00 15,000 shares |
9-10-2019 Insider Buy |
Sarah Reiter Chief Commercial Officer |
$6.48
CAGR »
|
$7,776.00 1,200 shares |
8-28-2019 Insider Buy |
Matthew T. Plavan Chief Financial Officer |
$8.73
CAGR »
|
$69,860.00 8,000 shares |
6-8-2017 Insider Buy |
Eric J. Rey Director |
$0.75
CAGR »
|
$3,750.00 5,000 shares |
5-20-2015 Insider Buy |
Agribusiness Co-investments I. Ltd Mandala >10% Owner |
$8.00
CAGR »
|
$3,000,000.00 375,000 shares |
5-20-2015 Insider Buy |
Uday Garg Director and >10% Owner |
$8.00
CAGR »
|
$3,000,000.00 375,000 shares |
5-20-2015 Insider Buy |
James Richard Reis Director |
$8.00
CAGR »
|
$100,000.00 12,500 shares |
5-20-2015 Insider Buy |
Darby E. Shupp Director and >10% Owner |
$8.00
CAGR »
|
$8,000,000.00 1,000,000 shares |
5-20-2015 Insider Buy |
Terri C. Bishop >10% Owner |
$8.00
CAGR »
|
$8,000,000.00 1,000,000 shares |
Also See: Institutional Holders of RKDA
Also See: SEC filings
Below we present the annualized performance delivered by Arcadia Biosciences stock since 8-4-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Arcadia Biosciences insider buying occurred is the ultimate
test of whether insiders were right about RKDA being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/07/2023 |
|
End date: |
05/06/2024 |
|
Start price/share: |
$4.68 |
|
End price/share: |
$2.00 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-57.37% |
|
Annualized Gain: |
-76.71% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,263.00 |
|
Years: |
0.75 |
|
Arcadia Biosciences Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Arcadia Biosciences insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding RKDA
|
|